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Lym-1 is a murine monoclonal antibody (mAb) that recognizes a
discontinuous epitope on the light chain of HLA-DR10 (Rose et al,
1996) and preferentially targets human malignant B cells (Epstein
et al, 1987). Owing to its substantial tumour selectivity and avidity
(Epstein et al, 1987) and its ability to activate complement-
mononuclear cell-and neutrophil-mediated cytolysis (Ottonello
et al, 1996; Valerius et al, 1997), Lym-1 looks like an attractive
candidate for developing mAb-based immunotherapies of B-lymph-
omas (Hu et al, 1989). Consistent with this view, promising results
have been obtained in clinical trials with Lym-1 immunotherapeutic
approaches to relapsed lymphomas (Hu et al, 1989; DeNardo et al,
1997). 
In recent years attention was focused on the possibility of
increasing Lym-1 mAb-dependent cell-mediated tumour cell lysis
by using biological response modifiers such as cytokines and
chemokines (Biddle et al, 1990; Ottonello et al, 1996; Vaickus
et al, 1990). Among various cytotoxic effectors, neutrophils have
been shown to be particularly susceptible to modulation by
cytokines such as GM-CSF, g-interferon and tumour necrosis
factor (Ottonello et al, 1996; Vaickus et al, 1990). Nevertheless,
few data are available for the human-mouse chimaeric Lym-1
mAb (chLym-1)3 (Hu et al, 1995). This mAb was indeed generated
by fusing the variable region genes of murine Lym-1 to human g1
and k constant regions (Hu et al, 1995), in order to enhance Lym-1
clinical potential and avoid the generation of human anti-mouse
antibodies. 
The present study was planned in the attempt to maximize the
expression of Lym-1 dependent neutrophil cytolytic potential.
Experiments were carried out with the previously applied cytolytic
system (Ottonello et al, 1996; Ottonello et al, 1999), using Raji
cells as a model of B-lymphoma target cells and chLym-1 instead
of Lym-1 as anti-target antibody. As effector cells, we used both
neutrophils from normal donors and neutrophils from patients
treated with G-CSF, i.e. phagocytes known to express the high-
affinity IgG receptor (FcgRI, CD64) other then the two low
affinity IgG receptors (FcgRII, CD32 and FcgRIII, CD16) consti-
tutively expressed by normal neutrophils (Kerst et al, 1993;
Michon et al, 1998). 
MATERIALS AND METHODS 
Culture medium and reagents 
The following culture medium was used: RPMI 1640 (Irvine
Scientific, S. Ana, Ca) supplemented with 10% heat-inactivated
(56˚C, 45 min.) fetal calf serum (FCS, HyClone Eur. Ltd,
Cramlington, NE) and 2 mM glutamine (Irvine Scientific) (RPMI-
FCS). Hanks’ balanced salt solution (HBSS) was from Irvine
Scientific. Ficoll Hypaque was purchased from Seromed, Berlin,
Germany. Sodium chromate51 Cr was from the Radiochemical
Centre, Amersham, England. Triton X-100 and ethidium bromide
were purchased from Sigma Chemical Co, St. Louis, Mo. Heparin
was obtained from Roche, Milano, Italy. Human recombinant 
GM-CSF was from Genzyme, Cambridge, MA. 
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The previously described (Hu et al, 1995) human-mouse
chimaeric Lym-1 mAb (chLym-1) was used as anti-target mAb for
the cytolytic assay. Moreover, the following mAbs were used:
anti-CD32 IV.3 (Fab fragments, Medarex, West Lebanon, NH),
anti-CD16 3G8 [F(ab¢)2 fragments, Medarex], anti-CD64 197
(mIgG2a, Medarex), anti-CD16 FITC-conjugated mAb 3G8
(IgG1, Pharmingen, San Diego, CA), anti-CD32 FITC-conjugated
mAb FL18–26 (IgG2b, Pharmingen), anti-CD64 FITC-conjugated
mAb 10.1 (IgG1, Pharmingen) and appropriate mouse IgG FITC-
conjugate isotype control 107.3 and 49.2 (Pharmingen). 
Neutrophil preparation 
Heparinized venous blood (heparin 10 U ml–1) was obtained from
healthy volunteers and from patients receiving G-CSF treatment
(G-CSF, Neupogen, 3–5 mg kg–1 for 3–5 days) after informed
consent. No healthy donor had an infectious disease or was under
medication at the time of and for 2 weeks before sampling. For
patients receiving G-CSF therapy to alleviate chemotherapy-
induced bone marrow toxicity and its clinical consequences, the
following criteria for drawing blood samples were used: (a) at
least 3 days of G-CSF therapy; (b) at least one day from the last G-
CSF administration; (c) an absolute neutrophil count > 2500 ml–1.
Neutrophils were prepared by dextran sedimentation, followed 
by centrifugation (400 g, 30 min) on a Ficoll-Hypaque density
gradient, as previously described (Ottonello et al, 1996).
Contaminating erythrocytes were removed by hypotonic lysis
(Ottonello et al, 1996). Neutrophils, resuspended in RPMI-FCS,
were > 97% pure and > 98% viable as determined by assay
described (Ottonello et al, 1996). 
Target cells 
Lymphoblastoid Raji cells (Ottonello et al, 1996) were used as
targets in the cytolytic assays. For cytolytic assays, 4 ´ 106 Raji
cells were labelled with 100 to 200 mCi sodium chromate 51Cr by
incubating for 1 h at 37˚C (final volume 0.5 ml, medium: RPMI
1640 plus 5% FCS). After washing, labelled cells were resus-
pended in RPMI-FCS. 
Cytolytic assays 
Cytolytic activity of neutrophils was measured as described else-
where in detail (Ottonello et al, 1996). Briefly, target cells (2 ´
104) were mixed with neutrophils at an effector: target ratio of
20:1, with and without chLym-1 monoclonal antibody and/or GM-
CSF appropriately diluted in RPMI-FCS. The effector: target ratio
of 20:1 was chosen on the basis of preliminary experiments.
Experiments were carried out in the absence or presence of the
various mAbs used to probe the cytolytic process. The assays were
carried out in triplicate and in a final volume of 150 ml, using
round bottom microplates (Falcon, Becton-Dickinson Italia,
Milano, Italy). After 14-h incubation in humidified atmosphere of
95% air and 5% CO2, the 51Cr-release was determined in the cell-
free supernatants. The percentage of cytolysis was calculated
according to the formula 100 ´ (E-S)/(T-S), where E is the cpm
released in the presence of effector cells, T is the cpm released after
lysing target cells with 5% Triton X-100, and S is the cpm sponta-
neously released by target cells incubated with medium alone. 
Immunofluorescence analysis 
Purified neutrophils (1 ´ 106 cells in HBSS) were incubated for 30
min at 4˚C with 4 mg/ml mAbs specific for surface antigens or
isotype mAb controls. Incubations were carried out in the presence
of polyclonal human IgG (4 mg ml–1) to inhibit non-specific mAb
binding to FcgRI. The cells were washed three times PBS supple-
mented with 1% bovine serum albumin and resuspended in PBS
for analysis on a flow cytometer (EPICS Profile, Coulter). For
each cell population, the relative fluorescence intensity (RFI) was
calculated as the ratio of mean linear fluorescence intensity of
relevant to irrelevant isotype controlled mAbs. 
Statistical analysis 
Results were expressed as mean ± 1 SD and/or a median with the
95% confidence interval. Statistical differences were analysed by
Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s
multiple comparisons test and by Mann-Whitney U-test.
Significance was accepted when P < 0.05. 
RESULTS 
Lysis of Raji cell by normal neutrophils in the presence
of chLym-1 and GM-CSF 
When added to 51Cr-labeled Raji cells in the presence of 
10 mg ml–1 chLym-1, normal neutrophils induced low but
detectable levels of target lysis, as measured by a 14-h 51Cr release
assay (Figure 1). Moreover, the addition of 1 ng ml–1 GM-CSF
consistently augmented neutrophil-mediated chLym-1-dependent
cytolysis (Figure 1). Consistent with previous observation (1,3),
normal neutrophils were incapable of mediating spontaneous lysis
and failed to display activity in the presence of GM-CSF alone, i.e.
in the absence of anti-target antibodies (Figure 1). As shown in
Figure 2, GM-CSF stimulated chLym-1-dependent lysis was
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Figure 1 Cytolysis mediated by normal neutrophils in the absence or
presence of 10 mg ml–1 chLym-1 and/or 1 ng ml–1 GM-CSF. 51Cr-labelled Raji
target cells were at 2 ´ 104. The neutrophil: target ratio was 20 : 1. The
incubation time was 14 h. Results are expressed as mean ± 1 SD. Nil (n =
14) vs. chLym-1 (n = 19): P < 0.01; chLym-1 (n = 19) vs chLym-1 + GM-CSF
(n = 19): P < 0.05; GM-CSF (n = 14) vs chLym-1 + GM-CSF (n = 19): 
P < 0.001. Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s
multiple comparisons test inhibited by 4 mg/ml mAb IV.3 (anti-CD32) and unaffected by 
4 mg ml–1 mAb 3G8 (anti-CD16). These data suggest that CD32,
i.e. Fcg receptor type II (FcgRII) in instrumental for neutrophil-
mediated lysis. It is of note that when the cytolytic assay was
carried out using 5 instead of 10 mg ml–1 chLym- 1, the lysis was
augmented significantly by mAb 3G8 (Figure 3). This suggests
that, in the presence of relatively low concentrations of anti-target
chLym-1 antibody, CD16, i.e. FcgRIII down-regulates neutrophil
cytolytic efficiency. 
Lysis of Raji cells by neutrophils from patients treated
with G-CSF 
As shown in Figure 4A, chLym-1 induced a dose-dependent Raji
cells lysis by neutrophils from a representative patient treated with
G-CSF. Moreover, the addition of 1 ng ml–1 GM-CSF enhanced
neutrophil lytic efficiency (Figure 4A). Finally, when tested in the
presence of 5 mg ml–1 chLym-1, the extent of the lysis was found to
depend on the effector : target ratio both in the absence and in the
presence of GM-CSF. On this basis, an effector target ratio of 20:1
and a chLym-1 concentration of 5 mg ml–1 were chosen for subse-
quent experiments. Figure 5 summarizes the results obtained by
testing the activity of neutrophils from 15 patients treated with G-
CSF. These cells exerted consistent levels of chLym-1 dependent
lysis (Figure 5). Moreover, GM-CSF enhanced significantly (P =
0.0042) the lytic efficiency, the level of lysis being 50% or more in
the majority of the cases (Figure 5). Finally, neutrophils from G-
CSF treated patients displayed a level of CD64 (FcgRI) and CD32
(FcgRII) expression significantly higher than cells from normal
donors (Figure 6). The cells from G-CSF treated patients had also
a CD16 (FcgRIII) surface expression lower than that shown by
normal neutrophils (Figure 6). 
Role of FcgR in the cytolysis mediated by neutrophils
from patients treated with G-CSF 
ChLym-1 dependent lysis by neutrophils from G-CSF treated
patients, carried out in the presence of GM-CSF, was slightly but
not significantly reduced by anti-CD64 mAb 197 (percent lysis:
46.25 ± 20.54 and 34.44 ± 13.81 in the absence and presence of
4 mg ml–1 mAb 197 respectively, mean ± 1 SD, n = 6; P = 0.393).
Similarly, a nonsignificant inhibition was observed by adding 4 mg
ml–1 of mAb IV.3 specific for CD32 (percent lysis: 40.37 ± 16.35
and 28.84 ± 23.22 in the absence or presence of mAb IV.3 respec-
tively, mean ± 1 SD, n = 5; P = 0.309). On the contrary, the lysis
was significantly inhibited by the simultaneous addition of both
mAb 197 and IV.3 to the system (Figure 7), whereas no effect was
detectable by using the anti-CD16 mAb 3G8 (Figure 7). Similarly,
neither mAb 197 nor mAb IV.3 inhibited the lysis mediated by
neutrophils from G-CSF treated patients in the absence of GM-
CSF (not shown), whereas the two mAbs added simultaneously
were effective (Figure 8). In addition, as shown in Figure 8, the
presence of anti-CD16 mAb 3G8 significantly enhanced chLym-1
dependent lysis, exerted by neutrophils from G-CSF treated
patients incubated with target cells in the absence of GM-CSF. 
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Figure 2 Effect of the anti-CD32 (FcgRII) mAB IV.3 Fab fragments and the
anti-CD16 (FcgRIII) mAb 3G8 F(ab')2 fragments on GM-CSF stimulated
chLym-1 mAb-dependent cytolysis by normal neutrophils. 51Cr-labelled Raji
cells were at 2 ´ 104. The neutrophil : target ratio was 20:1. The incubation
time was 14 h. ChLym-1 = 10 mg ml–1 and GM-CSF = 1 ng ml–1. Cytolysis in
the absence vs that in the presence of IV.3: P = 0.0286. Mann-Whitney U-
test 
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Figure 3 Effect of the anti-CD16 (FcgRIII) mAb 3G8 F(ab')2 fragments on
GM-CSF stimulated cytolysis by normal neutrophils in presence of 5 mg ml–1
chLym-1. 51Cr labelled Raji cells were at 2 ´ 104. The neutrophil : target ratio
was 20:1. The incubation time was 14 h. GM-CSF = 1 mg ml–1. Cytolysis in
the absence vs that in the presence of mAb 3G8: P = 0.0047. Mann-Whitney
U-test DISCUSSION 
The present study shows that: (a) human-mouse chimaeric Lym-1
mAb (chLym-1) is capable of triggering low level of cytolytic
activity in normal neutrophils through a process highly susceptible
of amplification by GM-CSF; (b) neutrophils from patients treated
with G-CSF display chLym-1 dependent cytolytic activities higher
than those achievable with normal effector cells and susceptible to
be further stimulated with GM-CSF; (c) normal neutrophils exert
their activity via FcgRII (CD32) whereas cells from G-CSF treated
patients act by using both FcgRII (CD32) and FcgRI (CD64); (d)
the efficiency of neutrophils from normal donors and that of cells
from G-CSF treated patients appears to be sensitive to a down-
regulation by FcgRIII (CD16). 
Previous studies from various research groups have shown that
neutrophils from G-CSF treated patients are more efficient that
those from healthy donors in mediating the lysis of various tumour
cells sensitised with polyclonal rabbit antiserum (Repp et al, 1991)
or murine monoclonal antibodies (Elsässer et al, 1996; Michon
et al, 1998; Valerius et al, 1993; Würflein et al, 1998). Among
these studies, the findings of Elsaässer and co-workers (Elsässer et
al, 1996) and those of Würflein and co-workers (Würflein et al,
1998) are closely related to the present ones. In fact, these authors
found that G-CSF primed neutrophils are more effective than
healthy donor neutrophils against Raji target cells sensitised with
murine Lym-1. The present observations extend these findings,
showing that the phenomenon occurs also by replacing murine
Lym-1 with chimaeric Lym-1 (chLym-1). Moreover, in agreement
with our previous observations obtained with murine Lym-1
(Ottonello et al, 1996), the exposure of normal neutrophils to GM-
CSF resulted in stimulated chLym-1 dependent cytolysis. The
stimulation by GM-CSF was also found using G-CSF primed
neutrophils, a finding particularly interesting also taking into
account the level of lysis achievable. Twelve of the fifteen cases
studied were indeed characterized by a GM-CSF stimulated
chLym-1 dependent lysis of 50% or higher. Moreover, three of
these cases had a lytic activity higher than 75%. Therefore, it
appears that in vivo administration of G-CSF induces a population
of circulating neutrophils particularly prone to exert chmAb-
dependent cytolysis and susceptible to further stimulation by GM-
CSF. 
Several papers dealing with the role of distinct FcgRs in murine
mAb-dependent tumour cell lysis by normal neutrophils have
shown the involvement of FcgRII (Würflein et al, 1998) or
FcgRIII (Gavioli et al, 1991) or both (Kushner and Cheung, 1989;
Kushner and Cheung, 1992). Our previous observations carried
out with murine Lym-1 and Raji target cells (Ottonello et al,
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Figure 4 Cytolysis mediated by neutrophils from a patient treated with G-
CSF. (A) Cytolysis at an effector : target ratio 20:1, in the presence of
different doses of chLym-1 and in the absence (u) or presence (l) of 
1 mg ml–1 GM-CSF. (B) Cytolysis at various effector : target ratios, in the
presence of 5 mg ml–1 chLym-1 and in the absence (u) or presence (l) of 
1 ng ml–1 GM-CSF. 51Cr labelled Raji target cells were always at 2 ´ 104. The
incubation time was 14 h 
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Figure 5 ChLym-1-dependent cytolysis mediated by neutrophils from
patients treated with G-CSF, in the absence (black bars) or presence (white
bars) of 1 ng ml–1 GM-CSF. 51Cr labelled Raji target cells were at 2 ´ 104.
ChLym-1 = 5 mg ml–1. The incubation time was 14 h. Percent cytolysis in
absence of GM-CSF: 30.4 ± 21.6; percent cytolysis in presence of GM-CSF:
52.1 ± 18.3, mean ± 1 SD, n = 15 1999) and the presents findings with the human-mouse chimaeric
construct of this mAb suggest that normal neutrophils use FcgRII
for mediating cytolysis. In general, this is also consistent with the
well-recognized role of this receptor as effective cytolytic trigger
molecule in neutrophil-mediated lysis of anti-FcgRII antibody-
bearing hybridoma cells (Elsässer et al, 1996; Graziano and
Fanger, 1990). Relatively few data are available on the interaction
of different FcgRs in cytolysis by neutrophils from subjects treated
with G-CSF (Elsässer et al, 1996; Würflein et al, 1998) and, to our
knowledge, data for the chLym-1 system are lacking. In contrast to
healthy donor neutrophils, which express FcgRII and FcgRIII
constitutively, G-CSF primed cells additionally express the high-
affinity FcgRI (Kerst et al, 1993; Michon et al, 1998; Repp et al,
1991). Although, as herein confirmed, the expression of the FcgRI
is relatively lower than that the other FcgRs (Kerst et al, 1993;
Michon et al, 1998; Repp et al, 1991), its intervention in murine
mAb-dependent tumour cell lysis by G-CSF primed neutrophils
takes place and depends on the isotype of the target-sensitising
mAb (Würflein et al, 1998). In particular, the lysis of Raji target
cells sensitized with mouse-murine chimaeric IgG1 mAb F3.3 to
HLA-class II by G-CSF primed neutrophils was found to be
partially but not significantly inhibited by blocking FcgRI with
mAb 197 (~ 40% inhibition) and FcgRII with mAb IV.3 (~ 15%
inhibition) (Würflein et al, 1998). The present experiments with
chLym-1 extend these observations. In fact, the IgG1 chLym-1-
dependent lysis by G-CSF-primed neutrophils, both in the absence
and presence of GM-CSF, was partially and not significantly
reduced by mAb 197 as well as mAb IV.3, but significantly inhibited
by the two anti-FcgR mAbs used simultaneously. Therefore, FcgRI
and FcgRII cooperate to trigger G-CSF primed neutrophils, under-
going direct as well as GM-CSF-stimulated chmAb-dependent lysis. 
It is well known that CD16, i.e. FcgRIII is the most abundant
neutrophil receptor for the Fc portion of IgG (Gessner et al, 1998;
Unkeless, 1989). This receptor is coupled to a phosphatidylinositol
anchor (Gessner et al, 1998; Unkeless, 1989) and, via interaction
with CD11b-CD18 integrins, activates certain phagocytic effector
functions such as phagocytosis and related neutrophil responses
including the respiratory burst (Porter and Hogg, 1998; Todd and
Petty, 1997; Zhou and Brown, 1994). Nevertheless, evidence for
its involvement as cytotoxic trigger in neutrophil-mediated mAb-
dependent tumour cell lysis is presently lacking (Elsässer et al,
1996; Ottonello et al, 1999). On the contrary, the present results
suggest that the anti-FcgRIII mAb 3G8 can augment chLym-1
dependent neutrophil induced cytolysis. Therefore, it appears that
FcgRIII may moderate the FcgRI- and FcgRII-mediated neutrophil
response to mAb-sensitized targets. In this view, the ability of G-
CSF to reduce the expression of FcgRIII might conceivably coop-
erate with the ability of G-CSF to induce FcgRI in order to provide
neutrophils with enhanced mAb-dependent potential. In agreement
with and related to these concepts, it has been suggested that shed-
ding of FcgRIII during neutrophil activation may permit a more
efficient binding of IgG-opsonized phagocytosable targets to
receptors, such as FcgRII, that are primarily responsible for the
triggering the lytic machinery of the neutrophil (Huizinga et al,
1990). 
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Figure 6 Expression of FcgRI (CD64), FcgRII (CD32) and FcgRIII (CD16)
by neutrophils from normal donors (white bars) and by neutrophils from
patients treated with G-CSF (black bars). Results are expressed as mean of
6 different subjects. CD64: healthy donors vs G-CSF treated patients: P =
0.0011; CD32: healthy donors vs G-CSF treated patients: P = 0.0325; CD16:
healthy donors vs G-CSF treated patients: P = 0.0076. Mann-Whitney U-test 
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Figure 7 Effect of the anti-CD64 (FcgRI) mAb 197 plus the anti-CD32
(FcgRII) mAb IV.3 Fab fragments and the anti-CD16 (FcgRIII) mAb 3G8
F(ab’)2 fragments on GM-CSF-stimulated chLym-1-dependent cytolysis by
neutrophils from G-CSF treated patients. 51Cr labelled Raji cells were at 
2 ´ 104. Neutrophil : target ratio = 20:1. Incubation time was 14 h. ChLym-1 =
5 mg ml–1. Cytolysis in the absence vs that in presence of 4 mg ml–1 mAb IV.3
plus 4 mg ml–1 mAb 197: P = 0.0159. Mann-Whitney U-test In conclusion, the present study provides rational bases for
raising optimized adjuvant immune-interventions in B-lymph-
omas, based on combined administration of chLym-1 and
cytokines such as G-CSF and GM-CSF, for instance, by including
G-CSF treatment prior to and GM-CSF treatment during mAb
administration. 
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Figure 8 Effect of the anti-CD64 (FcgRI) mAb 197 plus the anti-CD32
(FcgRII) mAb IV.3 Fab fragments and the anti-CD16 (FcgRIII) mAb 3G8
F(ab')2 fragments on chLym-1-dependent cytolysis by neutrophils from G-
CSF treated patients. 51Cr labelled Raji cells were at 2 ´ 104. Neutrophil :
target ratio was 20:1. Incubation time was 14 h. ChLym-1 = 5 mg ml–1.
Cytolysis in the absence vs that in presence of 4 mg ml–1 mAb IV.3 plus 
4 mg ml–1 mAb 197: P = 0.0286. Cytolysis in the absence vs that in presence
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